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Abstract
Background: Docosahexaenoic acid (DHA) and arachidonic acid (ARA) are major components
of the cerebral cortex and visual system, where they play a critical role in neural development. We
quantitatively mapped fatty acids in 26 regions of the four-week-old breastfed baboon CNS, and
studied the influence of dietary DHA and ARA supplementation and prematurity on CNS DHA and
ARA concentrations.
Methods: Baboons were randomized into a breastfed (B) and four formula-fed groups: term, no
DHA/ARA (T-); term, DHA/ARA supplemented (T+); preterm, no DHA/ARA (P-); preterm and
DHA/ARA supplemented (P+). At four weeks adjusted age, brains were dissected and total fatty
acids analyzed by gas chromatography and mass spectrometry.
Results: DHA and ARA are rich in many more structures than previously reported. They are most
concentrated in structures local to the brain stem and diencephalon, particularly the basal ganglia,
limbic regions, thalamus and midbrain, and comparatively lower in white matter. Dietary
supplementation increased DHA in all structures but had little influence on ARA concentrations.
Supplementation restored DHA concentrations to levels of breastfed neonates in all regions except
the cerebral cortex and cerebellum. Prematurity per se did not exert a strong influence on DHA
or ARA concentrations.
Conclusion: 1) DHA and ARA are found in high concentration throughout the primate CNS,
particularly in gray matter such as basal ganglia; 2) DHA concentrations drop across most CNS
structures in neonates consuming formulas with no DHA, but ARA levels are relatively immune to
ARA in the diet; 3) supplementation of infant formula is effective at restoring DHA concentration
in structures other than the cerebral cortex. These results will be useful as a guide to future
investigations of CNS function in the absence of dietary DHA and ARA.
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Background
Docosahexaenoic acid (DHA) is the most unsaturated
fatty acid in mammalian tissue. It is found at particularly
high concentration in retina [1] and cerebral cortex [2],
concentrated mainly in serine and ethanolamine phos-
phoglycerides [3]. Early observations led to studies show-
ing that low tissue DHA induced by dietary deficiency of
n-3 fatty acids results in compromised retinal function as
reflected by poor electroretinogram parameters [4-6] and
altered cognitive function [7]. Several hypotheses have
been proposed to explain the molecular role of DHA,
including its high degree of molecular flexibility as a com-
ponent of membrane phospholipids [8], improvement of
G-protein-coupled signaling [9,10], more favorable inter-
action with integral membrane proteins [11], its ability as
a free fatty acid to stabilize the electrical activity of ion
channels [12], and, very recently, as a precursor for com-
pounds protective of CNS function during ischemia [13].
The majority of DHA studies have focused on its role in
the cerebral cortex. There are few data on DHA concentra-
tions in most deep CNS structures at a gross level. For
instance, there are no studies of DHA concentrations in
the basal ganglia. These complex structures are involved in
a wide array of integrative functions involving motor
coordination, integration of visual signals, and psychiatric
and personality phenomena [14]. The globus pallidus,
caudate nucleus and putamen suffer specific, massive loss
of neurons in Huntington's disease, resulting in chorea,
dementia and psychiatric disturbances [15]. In Parkin-
son's disease, elimination of excessive output of the inner
segment of the globus pallidus by surgical removal or
lesion of the subthalamic nucleus has re-emerged as a
treatment for elimination of tremors [16]. The mecha-
nism of neural loss in these diseases remains elusive. Sim-
ilarly, there are few data on the fatty acid compositions of
the limbic regions, the thalamus or the midbrain.
Mammals obtain DHA nutritionally in two forms, either
as preformed DHA, found primarily in marine foods, or
via the dietary essential polyunsaturated fatty acid (PUFA)
α -linolenic acid (18:3n-3), from which DHA is synthe-
sized in various tissues. In vitro data suggest that in the
CNS, glia and cerebral endothelial cells, but not neurons,
synthesize DHA from 18:3n-3 and other precursor n-3
fatty acids [17]. Once formed, phospholipids containing
DHA are rapidly incorporated into neurons, and are con-
centrated in synaptosomes where they influence neuro-
transmitter content [18].
There has been intense interest in DHA and its influence
over function in the developing CNS. Randomized clini-
cal trials have shown that infant formulas with DHA
improve retinal and CNS function compared to formulas
containing only 18:3n-3 [19]. All studies also include ara-
chidonic acid (ARA) to prevent any possible negative
effects on growth reported in early studies [20]. Virtually
all clinical developmental studies in infants have exam-
ined visual and cognitive outcomes [19], and are limited
to sampling of blood for assessment of tissue responses to
supplementation, rather than the target CNS tissues.
Our first purpose in this report is to assess DHA and ARA
concentrations in normal, four week old baboons within
many CNS structures not previously studied. We also test
the hypothesis that supplemental DHA and ARA in infant
formula maintains CNS tissue concentrations similar to
those that are found for breastfed baboons. We test these




The Cornell Institutional Animal Care and Use Commit-
tee approved the care of animals and the Association for
Assessment and Accreditation of Laboratory Animal Care
(AAALAC) approved the facility. Female pregnant
baboons (Papio cynocephalus) obtained from the South-
west Foundation for Biomedical Research (San Antonio,
TX) were used in this study. After confirmation of preg-
nancy, 29 pregnant baboons were transported to Cornell
University (Ithaca, NY). The animals were involved in a
series of studies reported recently [21-24] and involving
only manipulation of dietary LCP and/or prematurity, as
presented here. A complete veterinary examination was
performed upon arrival in Ithaca. Pregnant baboons were
housed in individual cages in sight of at least one other
baboon.
Breastfed neonates were housed with their mothers in a
controlled-access nursery where the temperature and
humidity were 28°C and 50% respectively, and with a 14
h light and 10 h dark cycle, and consumed breastmilk
exclusively during the study period. All other neonates,
the "bottle-fed" groups, were removed and placed in a
nursery and consumed commercially available infant for-
mula without (minus, "-") or supplemented with (plus,
"+") long chain polyunsaturates (LCP).
Study design and diets
A diagram showing the timeline for CS and for euthanasia
is presented in Figure 1. All pregnant adult animals con-
sumed a commercial chow, yams, and fruits. The breast-
fed (B) and term groups (T+ and T-) were delivered
vaginally after spontaneous labor and averaged a birth-
weight of 863 grams, and there were no significant differ-
ences among groups. Further details are presented in
Table 1.BMC Medicine 2005, 3:11 http://www.biomedcentral.com/1741-7015/3/11
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Study timeline for the formula groups Figure 1
Study timeline for the formula groups. Time is represented as days from conception (conceptual age) or adjusted to time of 
normal term birth. The preterm (P) groups were taken at -24 days of gestational age by Cesarean section, while the term (T) 
groups were born spontaneously. All groups were euthanized at 28 days adjusted age, including the breastfed group (B).
Table 1: Characteristics of baboon neonates.
Breastfed B Term, no LCP T- Term, LCP T+ Preterm, no LCP P- Preterm, LCP P+
Gender 2F, 3M 5F, 2M 2F, 5M 3F, 2M 3F, 2M
Gestational age at CSa (d) Spontaneous Labor Spontaneous labor Spontaneous labor 156 ± 5 154 ± 2
Age at euthanasia (d)b 28 28 28.6 208 ± 2 208 ± 2
Birth weight (g)c 875 ± 65A 821 ± 119A 894 ± 96A 632 ± 61B 608 ± 71B
Body weight at euthanasia (g)d 1152 ± 177 1147 ± 113 1107 ± 145 1071 ± 187 1035 ± 220
Brain weight at euthanasia (g)d 103 ± 4 98 ± 6 100 ± 11 93 ± 8 94 ± 9
Data are expressed as mean ± SD.
aCS, Cesarean section.
bReported as birth age for B and T groups and conceptual (gestational) age for the P groups. The normal gestational period for baboons is 180–182 
days. Conceptual age for B and T at euthanasia was within 2 days of that for P+ and P-. Two animals in the T- group and one in the B group were 
42 days old at euthanasia. Other than these, all animals were about 208 days post-conception at euthanasia.
cValues that do not share common capital letter superscripts are significantly different (p <0.05).
dNo significant differences among groups.
Table 2: Content of selected LCP in baboon breastmilk and in formulas, as % (w/w).
Breastmilk T-,P- T+ P+
DHA 0.68 ± 0.22 ND 0.30 0.61 ± 0.03
20:5n-3+22:5n-3 0.84 ± 0.16 ND 0.10 0.18 ± 0.10
ARA 0.62 ± 0.12 ND 0.55 1.21 ± 0.09
ND: not detected
Preterm             Term
(CS)
          A n a l y s i s  
Conceptual Age      158                           182          196           210 
Adjusted Age          -24     0                14             28BMC Medicine 2005, 3:11 http://www.biomedcentral.com/1741-7015/3/11
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The concentrations of selected LCP in diets are presented
in Table 2, and are available in detail in other publications
[22,24]. Pregnant and, for the breastfed group, lactating,
females consumed a conventional commercial primate
diet for the entirety of the study. Normal primate meal
contains fish meal as a source of protein, which also adds
n-3 long chain polyunsaturated fatty acids (LCP). The
breastmilk of these baboons, sampled at four weeks post-
partum, contained about 0.68 ± 0.22% DHA, which falls
at the higher end of the range of fish-eating human
populations [25]. It also contained 20:5n-3 (0.34 ±
0.13%) and 22:5n-3 (0.51 ± 15%) as outlined in more
detail elsewhere [22].
The formulas with no LCP were identical for the term (T-
) and preterm (P-) groups. The term group that was sup-
plemented with LCP (T+) consumed formula fortified
with 0.3% energy DHA and 0.6% energy ARA, as pre-
sented in detail previously [24]. For four of these animals,
ARA was a component of phospholipid, while for three it
was a component of triglyceride. Otherwise, diets were
balanced and similar to commercial infant formula [24].
Preterm groups (P+ and P-) were delivered by Cesarian
section (CS) at about 24 days preterm, with details also
presented in Table 1. Preterm animals supplemented with
LCP (P+) consumed formula fortified with 0.6% en DHA
and 1.2% en ARA added as an encapsulated powder, and
kindly provided by Mead-Johnson Nutritionals [22].
DHA and ARA in these diets were about twice those in the
T+ diet, in an attempt to match the DHA content of breast-
milk while holding the DHA/ARA ratio constant at about
2:1.
Neonatal tissue was collected at about 28 days adjusted
age. This time point was chosen because previous data
showed significant neurobehavioral effects within the first
few weeks in term rhesus neonates [26]. The neonates
were weighed, ketamine was injected intramuscularly,
halothane general anesthesia was induced, and euthana-
sia was performed by exsanguination under continued
halothane anesthesia. The brain and spinal cord were
removed, wrapped in foil, frozen in liquid nitrogen and
stored at -80°C until analysis. A transection between the
brain and the spinal cord was made at the upper C1 level,
that is, between the first cervical spine and the skull base.
The brain weight listed in Table 1 is thus the sum of the
brain, cerebellum and the upper part of the cervical spinal
cord.
With the exception of cortical regions, CNS structures
were dissected and analyzed in their entirety. For cortex,
the top 3 mm of gray matter was carefully dissected from
the underlying white matter.
Lipid extraction and analysis
Total lipids were extracted from tissue homogenates by
methods reported previously [27]. Fatty acid methyl esters
(FAME) were prepared using 14% BF3 in methanol
(Sigma Chemical, St. Louis, Mo.). Butylated hydroxytolu-
ene (BHT) was added to solvents as an antioxidant and a
known quantity of freshly prepared heptadecanoic acid
(99+%, Sigma Chemical, St Louis, MO) in chloroform
was added as an internal standard to tissue samples just
before extraction. FAME were dissolved in heptane with
BHT and stored at -20°C until analysis.
FAME were analyzed using a Hewlett Packard 5890 series
II gas chromatography with a BPX 70 column (60 m ×
0.32 mm I.D. × 0.25 µm film; SGE, Austin, Tx) and H2 as
carrier gas. Quantitative profiles were calculated using
methyl-17:0 as an internal standard and an equal weight
FAME mixture (68A; Nuchek Prep, Elysian, Mn) to derive
response factors for each FAME. Chromatography condi-
tions and calibration details have been reported previ-
ously [27]. The DHA and ARA concentrations are
expressed as weight percentages of total fatty acids from
14 to 24 carbons.
Statistics
DHA data are presented as means ± SD. Weight percents
of DHA in various CNS regions were tested for significant
differences by Duncan's multiple range test with signifi-
cance declared at p < 0.05. For treatment effects, the
Fisher's least significant difference (Fisher's LSD) proce-
dure was used. A one-way analysis of variance (Anova)
was performed to test for equivalence of treatment means
for either DHA or ARA in a specific CNS region. When sig-
nificant at the p < 0.05 level, a t-test was performed on a
pairwise basis. Statistics were calculated using functions
provided in Excel 2000 for WinXP (Microsoft, Redmond,
WA). Duncan's multiple range test was performed to com-




Figure 2 is a schematic presentation of DHA concentra-
tions found in four week old baboon neonate CNS. The
coloring reflects DHA concentrations running from white
for highest to dark blue for lowest, as shown in the legend;
regions colored gray were not analyzed. The globus
pallidus has the highest DHA concentration at 15.8 ±
0.5% (w/w), while the optic nerve is lowest at 4.5 ± 0.4%.
The legend presents the results of Duncan's multiple range
test; regional DHA means that are not significantly differ-
ent share a common line.
Gray matter DHA was statistically different among cere-
bral cortex regions and averaged about 14%. This averageBMC Medicine 2005, 3:11 http://www.biomedcentral.com/1741-7015/3/11
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Baboon Neonate CNS DHA Map Figure 2
Baboon Neonate CNS DHA Map. Schematic diagram of four-week old baboon central nervous system with DHA concentrations 
color coded and ranked highest (white) to lowest (dark blue). Numbered lines in the parasagittal section refer to coronal sec-
tions; in this view, right side is shown with most of the right hemisphere removed for clarity. "Duncan" refers to Duncan's mul-
tiple range test; means sharing a line are not statistically different (p < 0.05). The colors each span 10% of the DHA 
concentration range.BMC Medicine 2005, 3:11 http://www.biomedcentral.com/1741-7015/3/11
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is greater than we reported elsewhere for cortices of simi-
lar baboons [27]. In previous studies, cerebrum was sam-
pled with an indeterminate contribution of white matter.
In the present study, about 3 mm of gray matter was care-
fully removed from the underlying white corona radia-
tion. Our results show that white matter is much poorer in
DHA than gray matter. The precentralis gray matter is sig-
nificantly richer in DHA (14.6 ± 0.9%) than the other cor-
tex lobes, while the temporal has the least DHA (12.2 ±
0.7%).
The distribution of DHA in five coronal sections is pre-
sented in an inset of Figure 2. Half of the central regions
of the brainstem and surrounding area are presented.
Coronal section 1 shows the globus pallidus, putamen
and caudate to have very high DHA concentrations
(>14.3%), while the surrounding white matter of the
coronal radiation is relatively low in DHA (5.5 ± 0.9%).
The corona radiation was sampled in regions with only
nerve fibers and devoid of neuronal soma, thus nuclei are
represented in Figure 2 in gray since they were not sam-
pled. Coronal sections 2–4 present views of the cingulate
gyrus, thalamus nuclei, geniculate bodies, pulvinar, col-
liculi and hippocampus, all rich in DHA. Coronal section
5 shows the white matter of the corpus callosum and coro-
nal radiation, both low in DHA.
Included in Figure 2 is a scale showing DHA values ranked
from highest to lowest and statistical differences. Close
examination shows that differences in DHA concentra-
tions are relatively small in consecutively ranked regions,
0.6% or less, except for the discontinuity between the lat-
eral geniculate (11.2 ± 1.6%) and corpus callosum (7.0 ±
1.3%). This dichotomy represents a demarcation between
predominantly gray or white matter, the latter of which, as
previously noted, is relatively poor in DHA.
CNS ARA concentrations
Figure 3 is a map of arachidonic acid concentrations in the
same CNS regions as presented in figure 2, and was
obtained from the same analyses. ARA concentrations
range from a high of 13.7 ± 0.5% in the amygdala to a low
of 6.8 ± 0.4% in the optic tract, to yield a range of about
2-fold in concentration compared to 3.5-fold for DHA. As
with DHA, gray matter is generally richer in ARA than is
white matter; however, in contrast to DHA, there is no dis-
continuity between gray and white matter ARA
concentrations.
Influence of treatments on CNS DHA and ARA
The results of analyses of DHA and ARA concentrations as
a function of treatments are presented in tables 3 and 4,
respectively. For DHA, one way ANOVA indicated that 23
of the 26 regions showed treatment effects, while only 8
of the 26 regions showed significant ARA treatment
effects.
We consider the randomized, breastfed control group (B)
to be a gold standard against which the others are com-
pared. With the exception of one region, the B group DHA
concentration was always among the greatest, while the P-
group was always among the lowest. More careful exami-
nation of the DHA statistical analysis reveals that the
responses of DHA concentrations among gray matter
regions fall into two distinct classes, as arranged in Table
3. For all lobes of the cerebral cortex, and for the cerebel-
lum, supplementation with 0.3% (T+) or 0.6% (P+) DHA
did not support tissue DHA concentrations similar to
those of the breastfed group. This is indicated by the
observation that the B group had significantly greater
DHA concentration than the other groups, denoted in the
table by "B>all". All other areas of gray matter investi-
gated, including the basal ganglia, limbic regions, thala-
mus and midbrain, fall in a class 2, in which
supplemental dietary DHA did restore DHA concentra-
tions to breastfed levels. This is denoted in the table by
"B>T-,P-", indicating that the B group DHA is not signifi-
cantly different from the T+ and P+ group DHA. All the
regions listed under class 2 have this pattern, and for two
regions, inferior colliculus and hippocampus, the B group
DHA is significantly greater than a supplemented group
(T+). Another dominant trend among gray regions is sig-
nificantly greater DHA concentrations in supplemented
groups (T+, P+) compared to unsupplemented groups (T-
, P-). We can conclude from these data that in gray matter,
DHA supplementation increases DHA concentrations in
most regions; with the critically important exceptions of
the cerebral cortex and cerebellum, supplemental dietary
DHA restores CNS DHA concentrations to breastfed
levels.
Trends in white matter are not as consistent as the two
classes of gray matter. Two of the six white matter regions
investigated did not respond to treatments (internal cap-
sule and spinal cord [includes white matter]). The B group
DHA was significantly greater than the others in three
regions but, uniquely, less than a supplemented group
(P+) in the corpus callosum.
The trends for ARA are very different from those for DHA.
As noted, treatments were ineffective at altering ARA
concentrations in 18 regions. Table 4 shows the eight CNS
regions that were significantly influenced by treatments.
Remarkably, the B group is of lower ARA concentration
than the P- group in every case, and this is significant in 7
of 8 regions. In every region, the P- group is among the set
of highest ARA concentration, and B is among the lowest.BMC Medicine 2005, 3:11 http://www.biomedcentral.com/1741-7015/3/11
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Baboon Neonate CNS ARA Map Figure 3
Baboon Neonate CNS ARA Map. Schematic diagram of four-week old baboon central nervous system with ARA concentrations 
color coded and ranked highest (white) to lowest (dark blue). See Figure 2 for key.BMC Medicine 2005, 3:11 http://www.biomedcentral.com/1741-7015/3/11
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Table 3: CNS DHA concentrations (mean ± SD, % w/w) for each treatment. One way Anova was significant (p < 0.05) for all structures 
except the spinal cord, internal capsule and medial geniculate. The right column shows the results of t tests. Gray matter falls into two 
classes: 1) LCP supplementation does not support DHA levels found for breastfed animals, detected for cerebral cortex and 
cerebellum; 2) LCP supplementation does support DHA levels, found in most other gray tissue (basal ganglia, limbic regions, thalamus 
and midbrain).
CNS Region Group Statistics
BT +T -P +P -
Gray,Class 1
Pre-Centralis 14.4 ± 0.9 12.6 ± 0.6 11.7 ± 1.0 13.0 ± 0.6 10.4 ± 0.7 [B>all; T+>P-; P+>T-,P-; T->P-]
Post-Centralis 14.1 ± 0.8 12.7 ± 0.8 11.7 ± 1.0 13.4 ± 0.6 10.4 ± 0.2 [B>T+,T-,P-; T+>T-,P-; P+>T-,P-; 
T->P-]
Occipital 13.9 ± 1.0 11.7 ± 0.9 10.7 ± 0.8 11.8 ± 0.1 8.7 ± 0.6 [B>all; T+>P+,P-; T->P+,P-; P+>P-]
Cingulate 13.4 ± 0.9 11.4 ± 0.7 10.7 ± 0.8 11.8 ± 0.8 9.5 ± 0.9 [B>all; T+>P-; P+>T-,P-; T->P-]
Frontal 12.7 ± 0.6 11.2 ± 0.8 10.6 ± 0.7 11.4 ± 0.4 8.4 ± 1.0 [B>all; T+>P+,P-; T->P-; P+>P-]
Temporal 12.2 ± 0.6 10.5 ± 1.1 10.3 ± 0.8 11.2 ± 0.5 9.0 ± 0.7 [B>all; T+,T-,P+>P-]
Cerebellum 12.6 ± 0.9 11.2 ± 0.7 10.6 ± 0.8 11.4 ± 0.2 7.7 ± 0.6 [B>all; T+>P-; T-,P+>P-]
Gray, Class 2
Globus Pallidus 15.8 ± 0.5 15.4 ± 0.6 12.7 ± 2.3 16.6 ± 0.3 13.4 ± 1.5 [B>T-,P-; T+>T-,P-; P+>T-,P-]
Putamen 14.7 ± 0.8 13.9 ± 0.9 13.5 ± 0.6 13.6 ± 1.3 11.6 ± 0.8 [B>T-,P-; T+,T-,P+>P-]
Caudate 14.3 ± 1.1 13.4 ± 0.8 13.0 ± 1.1 13.5 ± 0.8 11.3 ± 0.4 [B>T-,P-; T+,T-,P+>P-]
Superior Colliculus 15.2 ± 1.2 14.2 ± 1.1 13.6 ± 0.5 15.0 ± 0.4 13.4 ± 0.7 [B>T-,P-; P+>T-,P-]
Inferior Colliculus 14.4 ± 1.0 12.9 ± 1.4 13.4 ± 1.3 15.0 ± 0.6 13.4 ± 0.4 [B>T+; P+>T+,T-,P-]
Amygdala 12.0 ± 0.6 11.4 ± 0.6 10.8 ± 0.9 11.7 ± 0.5 9.4 ± 0.4 [B>T-,P-; T+,T-,P+>P-; P+>T-]
Hippocampus 13.0 ± 0.8 11.6 ± 0.5 10.6 ± 1.5 12.6 ± 0.5 9.0 ± 0.5 [B>T+,T-,P-; T+,T-,P+>P-; P+>T-]
Hypothalamus 12.0 ± 0.4 11.3 ± 0.6 11.0 ± 0.7 12.0 ± 0.8 10.6 ± 0.4 [B>T-,P-; T+>P-; P+>T-,P-]
Pulvinar 13.5 ± 0.6 12.7 ± 0.7 12.5 ± 1.0 14.6 ± 1.1 12.0 ± 0.4 [B>T-,P-; P+>all]
Thalamus DM 13.0 ± 1.0 12.4 ± 1.2 12.2 ± 0.9 13.5 ± 0.8 10.9 ± 1.3 [B>P-; T+,T-,P+>P-]
Thalamus VPL 12.9 ± 0.7 12.6 ± 0.9 12.2 ± 0.9 13.1 ± 1.7 10.3 ± 1.6 [B>P-; T+,T-,P+>P-]
Medial Geniculate 12.5 ± 1.3 12.8 ± 1.1 12.2 ± 0.9 12.6 ± 1.3 11.7 ± 0.8
Lateral Geniculate 11.2 ± 1.6 10.6 ± 0.9 9.5 ± 0.8 11.7 ± 0.7 8.8 ± 1.8 [B>T-,P-; T+>P-; P+>T-,P-]
White Matter
Corpus Callosum 7.0 ± 1.3 7.9 ± 0.7 6.4 ± 0.9 8.2 ± 0.7 6.3 ± 0.7 [T+>T-,P-; P+>B,T-,P-]
Internal Capsule 6.8 ± 1.0 7.0 ± 1.5 6.4 ± 0.7 7.9 ± 0.9 6.3 ± 1.4
Spinal Cord1 5.7 ± 0.3 6.0 ± 1.0 5.6 ± 0.5 6.2 ± 0.5 5.1 ± 0.6
Corona Radiation 5.5 ± 0.9 5.2 ± 0.9 4.4 ± 0.4 5.7 ± 0.8 4.7 ± 0.7 [B>T-; P+>T-,P-]
Optic Tract 4.8 ± 0.5 4.5 ± 0.4 4.3 ± 0.6 5.1 ± 0.3 3.9 ± 0.4 [B,T+>P-; P+>T+,T-,P-]
Optic Nerve 4.5 ± 0.5 4.0 ± 0.9 3.9 ± 0.4 4.8 ± 0.9 3.6 ± 0.3 [B>T-,P-; T+>P-; P+>all]
1Spinal cord is a mixture of white and gray matter.
Table 4: CNS ARA concentrations (mean ± SD, % w/w) for eight structures for which a one-way analysis of variance indicated at least 
one unequal mean (p < 0.05). Anova was not significant for the other 18 structures.
CNS Region Group Statistics
B T+ T- P+ P-
Occipital 13.2 ± 0.8 13.3 ± 0.7 13.6 ± 0.8 14.0 ± 0.5 14.3 ± 0.6 [P->B,T+]
Hypothalamus 11.7 ± 0.7 12.2 ± 0.6 11.4 ± 0.4 12.6 ± 0.7 12.9 ± 0.5 [T+,P+,P->T-; P+,P->B]
Superior Colliculus 10.1 ± 0.9 11.0 ± 0.8 10.6 ± 0.7 11.0 ± 0.6 11.7 ± 0.6 [T+,P+,P->B; P->T-]
Thalamus DM 10.0 ± 0.5 10.3 ± 0.6 9.6 ± 0.8 10.8 ± 0.6 10.7 ± 0.7 [T+,P+,P->T-; P+>B]
Corpus Collosum 9.9 ± 0.6 11.2 ± 0.5 10.2 ± 0.7 11.3 ± 0.5 11.4 ± 0.9 [T+,P+,P->B; T+,P+,P->T-]
Lateral Geniculate 9.5 ± 1.1 10.6 ± 0.6 9.9 ± 0.4 10.7 ± 0.5 10.5 ± 0.4 [T+,P+,P->B; P+>T-]
Inferior Colliculus 9.3 ± 0.5 10.5 ± 1.0 9.3 ± 0.7 10.3 ± 0.5 10.3 ± 0.4 [T+,P+,P->B,T-]
Optic Tract 6.8 ± 0.3 6.9 ± 0.4 7.2 ± 0.7 7.4 ± 0.3 7.7 ± 0.4 [P-,P+>B; P->T+]BMC Medicine 2005, 3:11 http://www.biomedcentral.com/1741-7015/3/11
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For both DHA and ARA, the effects of prematurity per se
are not strong. For DHA, the T+ group is significantly
greater than the P+ group in some cases, and similarly for
the T-/P- comparison. Because the groups were adjusted
age-matched, they were on formula for different periods:
the term groups were on formula for 4 weeks, while the
preterm groups were on formula for 7.5 weeks. For this
reason alone it is reasonable to expect that the P- group
would have lower DHA than the T- group. It should be
borne in mind that the supplementation for P+ was twice
that for T+, which partially compensates for this difference
in exposure to formula DHA. However, in every case, the
P+ DHA concentration exceeds that of the T- DHA
concentration, showing that the mild prematurity studied
here does not severely impair DHA accretion compared to
an unsupplemented term group. In other words, DHA
concentrations are greater in supplemented preterms than
they are in unsupplemented terms, indicating that prema-
turity itself does not impair DHA accretion.
Table 5 presents results for four other fatty acids of interest
in three selected CNS regions (occipital cortex, hippocam-
pus, corpus callosum). Neither 18:0 (stearic acid) nor
22:4n-6 (adrenic acid) showed any statistically significant
variation as a function of treatment in these regions; thus,
we report means and standard deviations pooled for all
treatments. Oleic acid (18:1n-9) was significantly differ-
ent in two regions but the difference in means was not
large, thus we also report pooled means. Importantly,
22:5n-6 (Osbond acid) was significantly elevated in the
CNS regions of the groups that did not have dietary DHA,
P- and T-. In 25 of 26 CNS regions (except thalamus DM),
P- was significantly elevated, while T- was significantly
elevated in 22 of 26 regions. Osbond acid generally rises
when DHA falls and it is considered a marker of DHA
insufficiency [22]. This fatty acid has been previously
reported to increase dramatically in n-3 fatty acid defi-
ciency [28] and to fall when deficient animals are sup-
plied with dietary DHA [29]. These data extend our
previous report [22] that 22:5n-6 levels rise throughout
the CNS when DHA is supplied in the diet with 18:3n-3
levels that are considered to supply sufficient n-3 fatty
acids for growth and development.
Discussion
Our fatty acid data were obtained from macroscopically
dissectible tissue and therefore contain a mix of cell types
and constituents that differ from region to region. Bourre
reported the DHA contents of cellular brain fractions of
soya oil fed 15-day-old rats [30] as neurons (8.2%),
astrocytes (10.6%), synaptosomes (8.5%), oligodendro-
cyte (5.1%) and myelin (5.8%). These data are qualita-
tively in accord with our DHA CNS results, considering
that gray matter is composed largely of neurons and glia
while white matter is composed principally of myelin and
oligodendrocytes. However, literature data clearly suggest
that DHA concentrations are not explained by a simple
mix of cells and cell types. For instance, adult human dor-
sal-medial (DM) thalamus total cell density and glia/neu-
ron indices are higher than the globus pallidus, though
DHA concentrations are lower [31]. Similarly, neuron
density (neurons/gram) in humans is in the order occipi-
tal lobe > precentralis > frontal lobe > hippocampus, a
gradation that also is not consistent with our DHA data
[32,33]. Data reported for neuron density of human
occipital lobe > temporal lobe > pre-centralis > thalamus
were also poorly correlated with our results [34]. Finally,
mean neuron volume in humans in the order
hippocampus > frontal > precentralis > occipital also
failed to show correlation with tissue DHA [32].
Table 5: Concentrations (mean ± SD) of selected fatty acids in three representative CNS regions. 18:0 (stearic acid) and 22:4n-6 
(adrenic acid) were not significantly altered by treatments in these CNS regions or in most others. While 18:1n-9 (oleic acid) was 
significantly different in occipital cortex and hippocampus but not corpus callosum, the magnitude of the differences was small and 
overall means are reported. 22:5n-6 (Osbond acid) was significantly elevated in all regions (except thalamus DM), for the P- and T- 
groups, similar to the patterns shown for the regions in this table.
Occipital Corpus Callosum Hippocampus
18:0a 19.5 ± 0.23 18.4 ± 0.72 19.3 ± 0.40
18:1n-9 10.6 ± 0.30b1 15.9 ± 0.80 11.5 ± 0.30b2
22:4n-6c 5.60 ± 0.25 7.060 ± 0.29 5.89 ± 0.19
22:5n-6 B T+ T- P+ P-
Occipital 1.97 ± 0.23 2.26 ± 0.32 2.47 ± 0.40 1.85 ± 0.23 2.39 ± 0.16 T-,P->B; T+,T-,P->P+
Corpus Callosum 1.16 ± 0.22 1.79 ± 0.26 1.43 ± 0.27 1.41 ± 0.22 1.94 ± 0.33 T+,P->B; T->T+; T+>P+; P->T-,P+
Hippocampus 1.86 ± 0.30 2.27 ± 0.40 2.28 ± 0.41 1.88 ± 0.16 2.33 ± 0.14 T+,T-,P->B; T+,T-,P->P+
a,cNo significant differences among groups (B, T+, T-, P+, P-).
b1Significant group differences: B<T-,P+
b2Significant group differences: B<T-,P+, P-BMC Medicine 2005, 3:11 http://www.biomedcentral.com/1741-7015/3/11
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A notable trend in the CNS regions richest in DHA is that
they are all involved in motor function. The basal ganglia
are all integrative centers for motor control and the globus
pallidus, caudate and putamen are among the top six in
DHA concentration. The cortical region with the highest
DHA concentration is the precentralis, which has long
been known as the motor cortex. The superior colliculus
is a major relay point for saccades, the rapid adjustment of
eye position. Of the six regions with the highest DHA, the
only region that is not known as a motor region is the
inferior colliculus, which plays a role in decoding spatial
information in auditory signal processing. Even here a
role in motor control system is possible and, notably, no
clear function has emerged for the dorsal part of this struc-
ture [35].
Recent studies in humans and animals suggest that even a
mild DHA deficit may impair motor function. Infant rhe-
sus monkeys on high DHA formula had improved
neuromotor scores compared to those on DHA-free diets
in the first month of life [26]. Human infants on formula
that induced low plasma DHA for the first four months of
life scored lower on one year evaluations of motor devel-
opment than those with better DHA status [36]. Bailey
motor development index scores for preterm infants on
DHA-containing formula were improved compared to
those on formulas with no DHA [37].
Our treatments are a strong test of the hypothesis that LCP
supplementation increases CNS LCP concentrations for
DHA and ARA, the two LCP that have garnered the most
attention for the developing human infant CNS. This is, in
part, because the randomized breastfed group is a true
gold standard for comparison, and because of the availa-
bility of CNS tissue for LCP analysis, neither of which are
available in human studies. DHA supplementation at a
level matched to that in the breastmilk of these control
baboons maintained DHA levels in many but not all CNS
regions. The cerebral cortex and cerebellum, both physi-
cally large regions requiring proportionately more DHA,
were unable to maintain levels similar to controls. We
have previously speculated [22] that this may be due to
the presence of significant amounts of 20:5n-3 and 22:5n-
3 in breastmilk (0.85%), which are thought to be much
more efficient precursors of DHA than 18:3n-3 [38],
quantitatively the most prominent omega-3 PUFA in
breastmilk and formula. Another important considera-
tion is that these regions have developmentally later peak
growth profiles than basal and limbic regions, which
develop early in gestation [39]. We can speculate that the
massive requirement for DHA imposed by aggressive
growth during this period renders these regions more
vulnerable to DHA insufficiency, and that biosynthesis
cannot keep up with demand. We thus accept the hypoth-
esis that supplemental DHA improves CNS tissue status,
with the proviso that current levels may be insufficient to
maintain levels in cortex. Notably, current formula DHA
levels in the USA are 0.15%–0.35% (w/w), which is about
1/4 to 1/2 that used in the P+ group, though the T+ group
was similar to commercial formulas with a DHA concen-
tration of about 0.3%. Finally, we note that previous
studies of neonatal rhesus monkeys have shown an
increase in cortex phosphatidylethanolamine DHA from
about 15% at birth to 22% and 34% at 22 months in fron-
tal and occipital cortex, respectively [28]. CNS demands
for DHA clearly continue well beyond the perinatal period
as the CNS matures.
The influence of our treatments on CNS ARA concentra-
tions is radically different from that for DHA. Most of the
CNS regions we investigated are nearly immune to sup-
plementation at levels twice that in current infant formu-
las (1.2%, w/w, for the P+ group). In fact, the significant
trends were, in some respects, opposite to what would
have been expected from the simple model that more die-
tary ARA should result in more CNS ARA. In particular,
the breastfed group tended to have the lowest ARA, while
the group longest exposed to ARA-free formula, the P-
group, tended to have the highest ARA concentrations.
Thus, the hypothesis that ARA-supplemented formula
always increases CNS ARA is rejected. CNS ARA concen-
trations are clearly under tighter control than DHA con-
centrations, a fact that may derive from ARA's role as
precursor of potently bioactive eicosanoids. Very recent
evidence suggests that DHA is also a precursor of oxygen-
ated derivatives, docosanoids; however the bioactivity of
these compounds and their biochemistry are not fully
described [13].
Conclusion
In summary, these data reveal that DHA and ARA concen-
trations in the CNS are highly region-specific and are
unexpectedly high in the deep CNS regions embedded in
white matter of much lower DHA and ARA concentration.
Supplementation improves DHA concentrations and in
all but the cerebral cortex, maintains DHA at levels similar
to that of breastfed controls. Prematurity per se does not
severely impair accretion of DHA. ARA is much less sensi-
tive to dietary manipulation than DHA, and the response
of CNS regions to ARA supplementation is complex.
Future research targeting functions controlled and medi-
ated by CNS structures other than the cerebrum and visual
system that are likely to be sensitive to DHA nutrition is
indicated.
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